ImmuPharma plc’s Cancer Drug Candidate IPP- 204106 Shows Complete Response to Tumours in Multiple Human Cancer Cell Lines

May 21, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, May 20, 2008-ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106.

Twitter
LinkedIn
Facebook
Email
Print

Preclinical Europe